<DOC>
	<DOCNO>NCT00368472</DOCNO>
	<brief_summary>The purpose study determine safety perampanel give adjunctive , long-term treatment patient refractory partial onset seizure .</brief_summary>
	<brief_title>4-Year Open-Label Extension Phase Parallel-Group Study E2007 Patients With Refractory Partial Seizures</brief_title>
	<detailed_description>This Open-Label Extension ( OLE ) study patient complete E2007-A001-206 ( NCT00144690 ) E2007-G000-208 ( NCT00416195 ) double-blind , placebo-controlled , dose-escalation , parallel-group study . This study consist 3 period : OLE Titration ( 12 week ) , OLE Maintenance ( 424 week ) , OLE Follow-up ( 4 week ) . During OLE Titration Period , participant titrate maximum tolerate dose ( MTD ) perampanel , maximum 12 mg/day . The OLE Maintenance Period begin completion OLE Titration Period ; participant remain dose achieved end OLE Titration Period unless dose adjustment tolerability reason necessary . Participants either withdrew study prematurely complete OLE Maintenance Period return final visit end 4-week OLE Follow-up Period .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>KEY INCLUSION CRITERIA : 1 . Have complete schedule visit include Visit 8 E2007A001206 ( NCT00144690 ) study Visit 9 E2007G000208 ( NCT00416195 ) study . 2 . Are reliable willing make available study period able record seizures report adverse event caregiver record report event . 3 . Females childbearing potential must continue practice medically acceptable method contraception ( e.g. , abstinence , barrier method plus spermicide , Intrauterine device ( IUD ) ) 8 week end OLE study . Those woman use hormonal contraceptive must also continue use additional approve method contraception ( e.g. , barrier method plus spermicide , IUD ) . 4 . Are age 18 70 year age , inclusive . 5 . Are least 40 kg ( 88 lb ) weight . 6 . Are currently treat stable dose one , maximum three license Antiepileptic drug ( AEDs ) know take medication ( ) direct . KEY EXCLUSION CRITERIA : 1 . Show evidence clinically significant disease ( cardiac , respiratory , gastrointestinal , renal disease , etc. , ) , opinion Investigator ( ) , could affect participant 's safety trial conduct . 2 . Show evidence significant active hepatic disease and/or bilirubin great 1.5 mg/dL . Stable elevation liver enzyme , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) due concomitant medication ( ) allow less two time upper limit normal ( ULN ) . 3 . Show evidence significant active hematological disease . White blood cell ( WBC ) count less equal 2500/microL absolute neutrophil count less equal 1000/microL . 4 . Clinically significant ECG abnormality , include prolonged QTc ( define great equal 450 msec ) . 5 . Presence major active psychiatric disease . Participants take stable dose selective serotonin reuptake inhibitor ( SSRI ) antidepressant allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Refractory</keyword>
	<keyword>Partial</keyword>
	<keyword>Seizures</keyword>
</DOC>